RFA-FD-25-020: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)

RFA-FD-25-020: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)

Executive summary

RFA-FD-25-020 is a reissued FDA NOFO administered through the Office of Orphan Products Development (OOPD) for R01-style clinical trials that can support new indications or label expansions for orphan products. The opportunity is specifically oriented to rare diseases and can fund phase 1, 2, or 3 studies where a measurable clinical path remains open but patient need is still high.

The program is meaningful for teams that already have a candidate product and can propose a realistic trial design that advances rare disease treatment development. It is not a broad discovery grant. It expects a study-ready project in a regulated clinical setting.

The opportunity has continuing cycles through at least 2028. The nearest 2026 and 2027 relevant cycle dates from the NOFO are:

• LOI: 2026-09-21 (optional), 2027-09-20 (optional)
• Application: 2026-10-20 and 2027-10-19

At-a-glance details

What this opportunity funds

The NOFO’s stated purpose is to fund clinical trial research for orphan products where evidence is needed to support a new indication or labeling change in rare diseases. This is a direct pipeline funding mechanism within the Orphan Products Grants Program and is intentionally practical:

• It is about execution, not only concept.
• It is designed around trial studies that can produce usable, regulatory-facing data.
• It is aimed at clinical development acceleration, including collaborative trial designs where that improves efficiency.

The NOFO prioritizes studies that address unmet need, and it explicitly encourages early and ongoing patient engagement in trial design. For teams asking “where this fits in the rare disease space,” this program is best viewed as one of the strongest FDA-linked translational routes for direct clinical data generation on already-identified products.

The program also references innovative trial design pathways (adaptive designs, basket/umbrella/platform approaches, and simulation-based methods). If your protocol is already conventional, it can still be valid; the innovation provision is an optional opportunity to request justified extra support when your design complexity warrants it.

Why it is different from standard discovery grants

Unlike exploratory funding that supports early-stage lab work, this NOFO is review-ready only when your product and protocol are in a clinical-trial posture. This matters because:

• You must specify how the work supports a new indication or label change.
• The application is expected to include concrete operational details: protocol, sites, monitoring, and product supply.
• Trial feasibility and execution quality are core success criteria.

Who this is for and who it is not for

This funding route is for teams ready to run a clinical trial for a rare disease product and willing to manage FDA-centric regulatory obligations. It is strong for small biotech, academic groups with active clinical capacity, disease foundations with research partners, and government-affiliated entities that can support a compliant trial.

It is generally not suitable for:

• Projects that are not clinical trials.
• Preclinical-only programs with no clear transition to human study execution.
• Teams not yet able to provide protocol-level preparation by submission time.
• Applicants looking for a long-gestation, unconstrained research exploration with no rare disease definition support.

The NOFO allows broad applicant categories (universities, nonprofits, for-profits, governments, and certain foreign organizations), but it remains a clinical-trial award first and a “research idea” award second.

Eligibility in practical terms

The NOFO is explicit on who can apply and what must be true on the core pages.

1) Applicant organization scope

The eligibility section lists a wide set of entities, including:

• Public/private higher education institutions
• Nonprofits (501(c)(3) and non-501(c)(3))
• Small businesses and larger for-profits
• Local and federal governments
• Additional public entities and regional groups
• Non-domestic entities where permitted by HHS/FDA framework

However, this breadth is not a shortcut for noncompliance: registration and submission requirements still apply to all.

2) Disease and population eligibility

Rare disease definitions follow the statutory threshold:

• Under 200,000 prevalence in the U.S. for chronic diseases
• Under 200,000 annual incidence for acute diseases

Diagnostics and vaccines may also be eligible only under defined thresholds. If you are claiming an orphan subset within a larger disease, the NOFO requires a clean rationale and supporting explanation.

3) Project eligibility

The NOFO is explicit on trial requirement:

• Must propose a clinical trial.
• Must target safety/efficacy information for unlabeled indication expansion or change.
• Proposed protocol should align with statutory and FDA requirements for IND/IDE context where applicable.

4) Registrations and compliance precondition

This is where many applications fail quietly:

• SAM registration (including any necessary CAGE/NCAGE elements where relevant)
• eRA Commons registration with required Signing Official and PI roles
• Grants.gov registration
• All registrations complete before submission

The NOFO is clear that delayed registrations are not accepted as a late-submission excuse.

5) Individual leadership profile

There is no narrow rigid career-stage gate in this NOFO text, but applicants should have a PI able to lead a trial-grade study and operate with FDA expectations. In review, leadership and execution readiness are heavily weighted.

Key dates, windows, and timeline discipline (2026/2027 focus)

As of the latest official open data, the relevant recurring 2026/2027 windows are:

• Letter of Intent (optional): 2026-09-21, 2027-09-20
• Application Due: 2026-10-20, 2027-10-19
• Resubmission-only deadlines: 2026-05-19, 2027-05-18

Submission time shown in the announcement is late-evening in local Eastern workflow for that category (11:59 PM equivalent timing in NOFO language). In practical terms, this still behaves like a hard cut-off: late submissions are rejected.

Important operational framing:

• Treat the first open cycle as a pilot prep cycle only if your protocol and site readiness are already strong.
• If this is your first application, consider using the optional LOI to test fit and collect program-level alignment notes before full submission.
• A missed registration state, missing clinical protocol, or unresolved IND/IDE access can invalidate an otherwise high-scoring scientific submission.

For your internal planning, build a backward timeline:

1. T-16 weeks: final sponsor/consortium confirmation and protocol direction finalization
2. T-12 weeks: registrations audit and preliminary package assembly
3. T-8 weeks: draft protocol + site letters + patient engagement evidence plan
4. T-4 weeks: full assembly and internal compliance review
5. T-2 weeks: submission dry-run and technical validation checks
6. T: final submission and real-time deadline monitoring

Application process and required materials

The NOFO requires conformance to the standard SF424 (R&R) instructions with NOFO-specific additions. Accepted submission paths:

• NIH ASSIST
• Institutional S2S solution with Grants.gov + eRA Commons
• Grants.gov Workspace + eRA Commons tracking

Key required materials for a compliant submission include:

1. Full final protocol package (with regulatory alignment where applicable)
2. Informed consent/assent documentation
3. Data management and sharing plan
4. Clinical endpoints, recruitment plan, and statistical approach
5. Evidence of product access and trial feasibility
6. Letters of support for study sites, product availability, and meaningful patient input
7. Clear budget justification, including any requests for innovation/top-up support

Mandatory protocol-side quality points

The NOFO requires the protocol to be operationally credible:

• Trial design must match the phase and the rare disease endpoint structure.
• Comparator strategy and data collection should be explicit.
• Monitoring plans should include who, what, and when at monitoring level (DSMB/monitoring committees as relevant).
• Human subjects protections and legal protections must be in place before review milestones.

Review criteria and practical review strategy

The NOFO says responsiveness is the first gate: if an application is non-responsive, it is not reviewed. Responsiveness and review quality are separate layers.

Responsiveness rules you must satisfy

• Clinical trial focus with clear rare disease criteria.
• Rare disease prevalence rationale documented.
• Project rationale explicitly tied to new indication or label change support.
• Regulatory alignment for protocol submission to IND/IDE where required.
• Required supporting letters and mandatory attachments.

Review lens the panel will apply

The NOFO review framework evaluates:

• Rationale quality: disease understanding and impact gap addressed.
• Study design and inferential power: can the trial produce interpretable evidence in stated time.
• Patient involvement quality: evidence that patient/caregiver input informed feasibility and design.
• Team and infrastructure credibility: PI, collaborators, site capacity, product supply.
• Budget and timeline realism: can funding support completion at requested speed.

Your best strategy is to write for this sequence in order:

1. Prove rarity and need clearly (eligibility and relevance).
2. Prove design validity (hypothesis, endpoints, comparators, statistics).
3. Prove execution readiness (sites, regulatory approvals, monitoring, supply).
4. Prove stakeholder integration (patient engagement, partnerships, industry/patient org links).

Common mistakes to avoid

Mistake 1: Generic science narrative with no trial operability

The NOFO reviewers and FDA gate review prioritize executionability. If your materials show strong science but weak site, supply, or protocol readiness, you will lose credibility.

Mistake 2: Missing registration and role assignments

SAM/eRA/Grants.gov registration is not clerical overhead; it is a hard requirement and is explicitly not an excuse for late submission.

Mistake 3: Weak patient and site evidence

The NOFO asks for letters and evidence of patient engagement and site capacity. This is not optional framing language. Include concrete documentation.

Mistake 4: Misaligned time assumptions

Project period and review timeline must match requested budget. The NOFO does allow continuation depending on performance and funding availability, but initial scope should still be realistic.

Mistake 5: Ignoring the protocol-IND/IDE timing

For drug and device studies, the NOFO requires protocol submission to the relevant FDA division in advance of grant deadline windows. This cannot be afterthoughted.

Preparation strategy before submission

Treat this as a “trial command post” process, not a writing task:

1. Map regulatory ownership
   List each protocol element and assign internal responsibility (PI, data manager, monitoring lead, regulatory lead, patient liaison).

2. Lock product and cohort assumptions
   Document intended population prevalence and justification for inclusion/exclusion in the context of rare disease thresholds.

3. Build a realistic trial monitoring architecture
   Put monitoring frequency, event reporting pathways, DSMB needs, and stopping criteria in a single operations sheet.

4. Collect letters early
   Request site and supplier letters with explicit language around capacity, duration, and product delivery reliability.

5. Validate applicant organization readiness
   Confirm registration IDs, PI credentials, and eRA Commons roles are active and mirrored across submission systems.

6. Pre-submit compliance pass
   Check every required NOFO-specific section (Appendix requirements, study monitoring plan, data sharing text, page limits for research strategy).

7. Prepare a concise backup submission version
   Create a submission-ready backup that removes non-essential prose if package size or clarity risks rise late in the process.

Frequently asked questions

Is this opportunity limited to U.S. organizations only?

No. The NOFO includes explicit pathways for non-domestic organizations and non-domestic components of U.S. organizations, but they must meet FDA/HHS and application rules.

Are multiple application windows open in the same year?

Yes. The NOFO includes recurring application deadlines. For 2026 and 2027, there are explicit due dates listed for both cycles, plus optional Letters of Intent a week earlier.

What is the maximum award amount?

Base total costs are shown as up to $650,000 per year for years 1 through 4. For eligible innovative and efficient trial approaches, the NOFO permits additional support up to $250,000 per year, capped at $900,000 per year.

Do foreign applicants need the same registrations?

Foreign entities that submit through this NOFO must still meet the relevant registration and submission requirements as described in the instructions and linked application materials.

Is patient engagement really required?

The NOFO states strong expectation for meaningful patient input and evidence of engagement in design planning, especially for feasibility and burden reduction.

Official links and next steps

Use only official channels for all critical details and submission mechanics:

• Official NOFO page (primary source): https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-020.html
• How to Apply guide: https://grants.nih.gov/grants/how-to-apply-application-guide.html
• Grants.gov workspace: https://www.grants.gov
• FDA Orphan Products Grants program page (for related procedural context): https://www.fda.gov

If you are not fully ready for a full submission this cycle, use this NOFO as a prep checklist instead of waiting passively. The program supports clinically mature teams, and teams that align early with operational readiness have a materially better chance of passing compliance and responsiveness gates.